spacer
home > ebr > summer 2004 > the ipo window reopens - are you ready?
PUBLICATIONS
European Biopharmaceutical Review

The IPO Window Reopens - Are you Ready?

Whisper it quietly, but the IPO window may just have reopened for European biotechs. Ark Therapeutics' flotation in March this year has led to a spate of similar launches of biotech stocks onto the public markets after a dearth of opportunities in recent years. The position undoubtedly remains volatile. Only the best companies will be allowed to list and, as ever, due diligence will be key. This article looks at the importance of legal due diligence in the context of an impending IPO and asks are you ready to take advantage of the IPO window - which may yet prove shortlived.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Patrick Martin, Partner and Martin Finnegan, Senior Solicitor at McGrigors

Patrick Martin is a Partner and Corporate and Commercial Lawyer at McGrigors, with a particular emphasis on the health care and life sciences fields, acting for both investors and companies. He has advised on numerous technology start-ups and spin-outs, fundraisings and private placements for biotech companies and IPOs. Patrick has specialised in private equity work for over 14 years.


Martin Finnegan is a senior Corporate Solicitor at McGrigors and part of the firm's public equity group. Martin has advised on numerous IPOs and public equity issues acting for sponsors and companies, and is a member of the legal committee of the Quoted Companies Alliance (QCA).

spacer
Patrick Martin
spacer
spacer
spacer
Martin Finnegan
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

The CPhI Annual Report

The global pharmaceutical landscape is evolving at an extraordinary pace as manufacturing capabilities, drug development technologies, and regulation advances creating new ways of innovating drugs and better serving patients.
More info >>

White Papers

PROTEIN:PROTEIN INTERACTION ANALYSIS

IBA GmbH

Groth et al., 2007 and Jasencakova et al., 2010 Protein:protein-interactions (PPI) govern almost all important processes in living organisms. Thus, their rapid and accurate determination and investigation is a major challenge in life sciences. The extremely efficient and fast One-STrEP (Twin-Strep) system is suitable for the isolation of functional protein complexes and subsequent mass spectrometry analysis leads to the identification of protein complex components (Junttila et al., 2005) as it is shown in the following studies.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement